LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced that its Venezuelan subsidiary, LATAMEDAI VE, has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration aims to design, develop, test, and evaluate customized technology intended to support workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis.
The proposed technology is expected to incorporate software tools designed to organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. The parties will begin by identifying specific workflows to be addressed, defining technical and operational requirements, and establishing a phased development and testing process. They also intend to set up confidentiality, information-security, data-management, and access-control procedures.
The initiative is part of LataMed AI's broader strategy to develop digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, and other ecosystem participants. Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
The collaboration could potentially expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications beyond its patient-facing telemedicine services. If successfully developed and implemented, management believes the resulting technology may provide a framework that could be adapted for other organizations in Venezuela and Latin America. However, any future expansion would remain subject to separate agreements, successful development and testing, operational readiness, applicable regulatory requirements, and the needs of participating organizations.
The parties will also evaluate ownership, licensing, permitted use, and protection of any intellectual property developed through the collaboration. The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation schedule, commercial deployment, reduction in costs or timelines, scientific or regulatory outcomes, revenue, or expansion.
This partnership underscores the growing trend of integrating AI into pharmaceutical and laboratory operations, potentially improving efficiency and accuracy in critical workflows. For the industry, such collaborative efforts could lead to more streamlined processes and enhanced decision-support capabilities, ultimately benefiting patients and healthcare systems. The announcement also highlights LataMed AI's commitment to expanding its technological footprint in Latin America's healthcare sector.
For more information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
